Post-earnings recap
Reported
Thu, Aug 13, 2026
EPS actual
$-1.23
EPS est.
$-2.06
EPS surprise
+40.23%
1-day move
-0.14%
Nektar Therapeutics reported a narrower-than-expected EPS loss, which was a positive surprise for investors. However, the stock reacted slightly down by 0.14%, likely due to the lack of revenue data and no updated guidance. The company is focusing on its promising drug REZPEG, which could address significant patient needs in the future.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.23 | N/A | +40.23% |
| Cash | $1.02B | N/A | N/A |
| Debt | $0 | N/A | N/A |
Management expressed optimism about the ongoing Phase III trials for REZPEG, highlighting strong physician interest. They also noted the company's solid cash position and lack of debt.
Physician enthusiasm for REZPEG's novel mechanism of action is high.
REZPEG has the potential to address significant unmet needs in atopic dermatitis and alopecia areata.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±20.3%
Nektar Therapeutics is a pharmaceutical company focused on developing innovative therapies for patients with serious diseases. With a market cap of $3 billion, it operates in the health care sector, which is increasingly important as demand for new treatments continues to grow.
Last quarter
In Q1 2026, Nektar reported an EPS of $-1.82, which was slightly worse than expectations. The stock reacted negatively, falling 2.02% the next day.
Management promises and guidance
EPS beat streak
1Q
EPS beat rate
63%
Avg EPS surprise
-155.56%
Avg 1-day reaction
-0.86%
Overall, expectations are mixed as Nektar has struggled with profitability but has potential in its drug pipeline. Investors will be watching closely for any signs of improvement.
Bull case
If Nektar can demonstrate a significant reduction in EPS losses and provide positive updates on its drug development, it could boost investor confidence and drive the stock higher.
Bear case
Conversely, if the company reports larger-than-expected losses or delays in its clinical trials, it could lead to further declines in stock price.
Key metrics to watch
Earnings Per Share (EPS)
$-1.74EPS is a critical measure of profitability, and investors will be keen to see if Nektar can narrow its losses this quarter.
Revenue Growth
N/AWhile specific revenue estimates are not available, any growth in revenue would indicate progress in product development and market acceptance.
The print will turn on these.
Q1
What will the EPS be for Q2-2026?
A narrower loss than expected could indicate improved operational efficiency and boost investor sentiment.
Q2
What updates will be provided on clinical trials?
Progress in clinical trials is crucial for Nektar's future growth and can significantly impact stock performance.
Why consensus could be wrong
The Street may underestimate Nektar's potential for narrowing losses this quarter, as recent operational changes could lead to better-than-expected results.
Supporting evidence
Nektar's history of surprising the market with better-than-expected EPS in previous quarters.
The options market is pricing a significant move, indicating heightened expectations.
Management's commitment to reducing costs could lead to improved margins.
Key risk
If EPS comes in better than $-1.74, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The market is debating whether Nektar can turn around its financial performance and maintain momentum in its drug development pipeline.
Bull confirmed if
An EPS loss of less than $-1.74 would confirm the bull case and suggest operational improvements.
Bear confirmed if
An EPS loss greater than $-1.82 would confirm the bear case and indicate ongoing struggles.
What the market is pricing for the move.
Implied Move
±11.48%
Historical Avg
±1.8%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.
Options are pricing ±11.5% while NKTR has averaged ±1.8% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
62.9%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Nektar beats EPS expectations and raises guidance, history suggests the stock could rise by around 1.58% the next day.
In line / cautious
If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.
Miss
If Nektar misses EPS expectations, history suggests a potential decline of around 0.10% the next day.
The lines on the call that would change the story.
R&D Spending
N/AInvestments in research and development are crucial for pharmaceutical companies, and insights into spending can signal future product pipelines.